一名接受奥瑞珠单抗治疗的患者在接种辉瑞新冠疫苗后抗新冠病毒刺突蛋白抗体反应呈阴性 - Suppr

Suppr

超能文献

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.

作者信息

Khayat-Khoei Mahsa, Conway Sarah, Rubinson Douglas A, Jarolim Petr, Houtchens Maria K

机构信息

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

出版信息

J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.

DOI:10.1007/s00415-021-10463-3

PMID:33638680

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910800/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5538/7910800/ae626d9ed693/415_2021_10463_Fig1_HTML.jpg

相似文献

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.

J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.

Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.

J Neurol. 2021 Nov;268(11):3998-3999. doi: 10.1007/s00415-021-10547-0. Epub 2021 Apr 16.

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.

J Int Med Res. 2021 Sep;49(9):3000605211044378. doi: 10.1177/03000605211044378.

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).

Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.

Neurol Sci. 2021 Sep;42(9):3523-3526. doi: 10.1007/s10072-021-05397-7. Epub 2021 Jun 15.

Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study.

Mult Scler Relat Disord. 2021 Jul;52:103014. doi: 10.1016/j.msard.2021.103014. Epub 2021 May 7.

Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.

Clin Chim Acta. 2021 Jul;518:9-16. doi: 10.1016/j.cca.2021.03.007. Epub 2021 Mar 17.

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.

Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.

J Korean Med Sci. 2021 May 31;36(21):e158. doi: 10.3346/jkms.2021.36.e158.

The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.

Przegl Epidemiol. 2021;75(1):3-13. doi: 10.32394/pe.75.01.

引用本文的文献

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.

Neurol Neuroimmunol Neuroinflamm. 2023 Apr 24;10(4). doi: 10.1212/NXI.0000000000200118. Print 2023 Jul.

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.

Int J Mol Sci. 2022 Jul 30;23(15):8485. doi: 10.3390/ijms23158485.

Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.

Ann Clin Transl Neurol. 2022 Aug;9(8):1321-1331. doi: 10.1002/acn3.51628. Epub 2022 Jul 19.

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets.

J Cent Nerv Syst Dis. 2021 Dec 2;13:11795735211060118. doi: 10.1177/11795735211060118. eCollection 2021.

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.

J Int Med Res. 2021 Sep;49(9):3000605211044378. doi: 10.1177/03000605211044378.

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.

Vaccine. 2021 Oct 1;39(41):6111-6116. doi: 10.1016/j.vaccine.2021.08.078. Epub 2021 Sep 2.

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.

CNS Drugs. 2021 Sep;35(9):985-997. doi: 10.1007/s40263-021-00843-8. Epub 2021 Aug 9.

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.

Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.

Mult Scler Relat Disord. 2021 Jul;52:102983. doi: 10.1016/j.msard.2021.102983. Epub 2021 May 4.

Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.

Mult Scler Relat Disord. 2021 Jul;52:102922. doi: 10.1016/j.msard.2021.102922. Epub 2021 Mar 25.

本文引用的文献

Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.

Mult Scler Relat Disord. 2021 Apr;49:102777. doi: 10.1016/j.msard.2021.102777. Epub 2021 Jan 19.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.

Vaccines for COVID-19.

Clin Exp Immunol. 2020 Nov;202(2):162-192. doi: 10.1111/cei.13517. Epub 2020 Oct 18.

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use.

J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01742-20.

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.

Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.

Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1.

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.

Mult Scler Relat Disord. 2020 Sep;44:102341. doi: 10.1016/j.msard.2020.102341. Epub 2020 Jun 26.

The COVID-19 Serology Studies Workshop: Recommendations and Challenges.

Immunity. 2020 Jul 14;53(1):1-5. doi: 10.1016/j.immuni.2020.06.012. Epub 2020 Jun 23.

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.

Mult Scler Relat Disord. 2020 Sep;44:102323. doi: 10.1016/j.msard.2020.102323. Epub 2020 Jun 22.

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.

Mult Scler Relat Disord. 2020 Sep;44:102315. doi: 10.1016/j.msard.2020.102315. Epub 2020 Jun 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验